Earnings release
Page 1
CLOSE THIS WINDOW 01/16/2026 RNS Number : 1316P Genus PLC 16 January 2026 16 January 2026 Genus plc ("Genus" or the "Group") Half Year Trading Update - Ahead of expectations Genus (LSE: GNS), a leading global animal genetics company, publishes the following unaudited trading update for the six months ended 31 December 2025 ("H1 FY26"). Genus performed strongly in H1 FY26 and the Board expects to report first half Group adjusted profit before tax (excluding the BCA milestone payment referenced below) of approximately £50m in actual currency, which is ahead of ourexpectations. Including the BCA milestone payment, first half Group adjusted profit before tax is expected to beapproximately £55.6m in actual currency. Following the Group's AGM trading update in November 2025, PIC trading continued to be strong and ABS traded asexpected. The Board now expects Group FY26 adjusted profit before tax (excluding the BCA milestone payment ) to be moderately above the top-end of current market expectations . On 4 September 2025, Genus announced the accelerated formation of its porcine joint venture in China . The Group is pleased to confirm that formation of the joint venture received regulatory approval from SASAC in December 2025, which has also triggered the final $7.5m (c. £5.6m) milestone payment from BCA to Genus. Genus now expects formation of the Chinese porcine joint venture and receipt of the milestone cash payment in its fiscal third quarter. Genus will announce its interim results for the six month period from 1 July 2025 to 31 December 2025 on 26 February 2026. For further information please contact: Genus plc Tel: +44 (0)1256 345 970 Jorgen Kokke, Chief Executive Officer Andy Russell, Chief Financial Officer Anand Date, Investor Relations & Sustainability Director Burson Buchanan Tel: +44 (0)207 466 5000 Charles Ryland; Mark Court; Toto Berger; Jamie Hooper About Genus Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement byapplying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors. Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus'scustomers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairyand meat supply chains. The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, thebiotechnology used to improve them and its global supply chain, technical service and sales and distribution network. The PRRS Resistant Pig is a market leading innovation in gene editing which Genus is looking to commercialise in the porcineindustry once further regulatory approvals are obtained. With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents,with research laboratories located in Madison, Wisconsin, USA. Footnotes Group adjusted profit before tax excludes the PRP-related milestone payment from BCA triggered by receipt of regulatoryapproval from SASAC and the financial impact from the planned formation of the Group's porcine joint venture in China The company compiled consensus estimate range for Group FY26 actual currency adjusted profit before tax is £82.7m to£85.0m with an average midpoint of £83.6m, and is based upon 9 analyst estimates Accelerated Chinese porcine joint venture formation China's State-owned Assets Supervision and Administration Commission of the State Council ("SASAC") PRRS (Porcine Reproductive and Respiratory Syndrome) Resistant Pig ("PRP") 1 1 2 3 4 5 1 4 2 3 4 5
Page 2
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END TSTSFIFWIEMSEFF CLOSE THIS WINDOW